Showing 4221-4230 of 5771 results for "".
- Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathyhttps://modernod.com/news/ocuphire-initiates-zeta-1-phase-2-clinical-trial-investigating-apx3330-in-diabetic-retinopathy/2479060/Ocuphire Pharma announced that it has screened the first patient in ZETA-1, a phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR). Effects on diabetic macular edema will be explored as a secondary outcome. A number o
- FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/fda-approves-bausch-lomb-clearvisc-dispersive-ophthalmic-viscosurgical-device-ovd/2479058/Bausch + Lomb, announced that the FDA has approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. “OVDs play a critical role in ophthalmic surgery, and ClearVisc offers surgeons unique advantages that are designed to contribute to surgical safety
- Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directorshttps://modernod.com/news/second-sight-medical-products-names-dean-baker-and-alexandra-larson-to-its-board-of-directors/2479051/Second Sight Medical Products announced that the company’s Board of Directors has appointed two new members, Dean Baker, PhD, and Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board. “We are honored and excited to add these two very talented individuals
- Oxurion Enters Into a Capital Commitment of Up to €30 Million With Negma Grouphttps://modernod.com/news/oxurion-enters-into-a-capital-commitment-of-up-to-e30-million-with-negma-group/2479054/Oxurion announced that is has agreed to a capital commitment of up to €30 Million with Paris-based financial institution Negma Group. Negma Group has committed to subscribe to up to €30 million in equity in tranches over a 12-month period through mandatory convertible bonds at Oxurion’s sole dis
- David R. Guyer, MD, to Step Down from Iveric Bio Board to Rejoin Venture Fundhttps://modernod.com/news/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund/2479050/Iveric bio announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt
- New Educational Resource On Importance of Eye Protection in Sports/Recreational Activititeshttps://modernod.com/news/new-educational-resource-on-importance-of-eye-protection-in-sports-recreational-activitites/2479046/The International Sports Vision Association (ISVA) and Zyloware Eyewear announced the launch of Protect. Prevent. Play., a new educational resource designed to help eye care professionals educate parents, coaches, teachers, athletic trainers and athletes of all ages and skill levels abou
- Horizon Therapeutics to Resupply Market With Tepezza for the Treatment of Thyroid Eye Disease (TED) Beginning in Aprilhttps://modernod.com/news/horizon-therapeutics-to-resupply-market-with-tepezza-for-the-treatment-of-thyroid-eye-disease-ted-beginning-in-april/2479043/Horizon Therapeutics announced that the FDA has approved a prior approval supplement (PAS) to the previously approved Biologics Licensing Application (BLA) giving Horizon authorization to manufacture more Tepezza drug product resulting in an increased number of vials with each manufacturing slot.
- AdaptDx Pro’s On-Board AI Technician Now Speaks in Multiple Languageshttps://modernod.com/news/adaptdx-pros-on-board-ai-technician-now-speaks-in-multiple-languages/2479039/MacuLogix announced its first major software upgrade for its AdaptDx Pro portable dark adaptometer. Once the software is automatically downloaded and installed, the artificial intelligence-driven onboard technician, T
- Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenavahttps://modernod.com/news/outlook-therapeutics-reports-positive-safety-profile-from-norse-three-study-for-lytenava/2479037/Outlook Therapeutics announced positive topline results from its NORSE THREE open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases. Topline results from the open-label safety study demonstrated that ONS-5010 showed no unexpecte